Ashion is now a part of Genomic Health, Inc. (GHI), a wholly owned subsidiary of Exact Sciences, Corporation. By combining our leading portfolio of products, we’re helping people make the most challenging decisions with confidence, providing earlier answers and life-changing treatment guidance. We are pleased to make the GEM ExTra assay a part of that portfolio. Therefore, the GHI Billing and Reimbursement policies, as well as patient financial assistance programs, will be available for GEM ExTra patients. 

Learn more about GHI’s Billing and Coverage programs HERE.